Skip to main content
SpringerLink
Log in

PTPN12 inhibits oral squamous epithelial carcinoma cell proliferation and invasion and can be used as a prognostic marker

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Protein tyrosine phosphatase nonreceptor type 12 (PTPN12) has been recognized as a tumor suppressor gene that may inhibit tumor growth. However, PTPN12 expression in oral squamous carcinoma (OSCC) has not been studied. We showed reduced expression of PTPN12 in OSCC tissues. Decreased PTPN12 expression was significantly associated with clinical stage of the disease (P < 0.01). Moreover, reduction in PTPN12 correlated with the overactivation of STAT3. PTPRD negatively related to STAT3 phosphorylation (R = −0.535). Low expression of PTPN12 and high level of phosphorylation of STAT3 correlated with poor prognosis. Overexpression of PTPN12 inhibited proliferation and migration in OSCC cells. PTPN12 was associated with STAT3 and induced STAT3 dephosphorylation. Moreover, our results suggested that PTPN12 might function through binding and dephosphorylation of STAT3. Therefore, PTPN12 is a potential marker for prognosis of OSCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Perez-Ordoñez B, Beauchemin M, Jordan RC. Molecular biology of squamous cell carcinoma of the head and neck. J Clin Pathol. 2006;59:445–53.

    Article  PubMed  Google Scholar 

  2. Wang Y, Zhou X, Song Y, Ji X, Zhang A, Zhang G, Gao Z. The mismatch repair gene hPMS1 (Human postmeiotic segregation1) is down regulated in oral squamous cell carcinoma. Gene. 19 April 2013. [Epub ahead of print].

  3. Laczmanska I, Sasiadek MM. Tyrosine phosphatases as a superfamily of tumor suppressors in colorectal cancer. Acta Biochim Pol. 2011;58:467–70.

    PubMed  CAS  Google Scholar 

  4. Harris IS, Blaser H, Moreno J, Treloar AE, Gorrini C, Sasaki M, Mason JM, Knobbe CB, Rufini A, Hallé M, Elia AJ, Wakeham A, Tremblay ML, Melino G, Done S, Mak TW. PTPN12 promotes resistance to oxidative stress and supports tumorigenesis by regulating FOXO signaling. Oncogene. 25 Feb 2013. [Epub ahead of print].

  5. Kohno T, Otsuka A, Girard L, Sato M, Iwakawa R, Ogiwara H, Sanchez-Cespedes M, Minna JD, Yokota JA. Catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene. Genes Chromosomes Cancer. 2010;49:342–52.

    PubMed  CAS  Google Scholar 

  6. Meehan M, Parthasarathi L, Moran N, Jefferies CA, Foley N, Lazzari E, Murphy D, Ryan J, Ortiz B, Fabius AW, Chan TA, Stallings RL. Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase a oncogene. Mol Cancer. 2012;11:6.

    Article  PubMed  CAS  Google Scholar 

  7. Villa-Moruzzi E. PTPN12 controls PTEN and the AKT signalling to FAK and HER2 in migrating ovarian cancer cells. Mol Cell Biochem. 2013;375:151–7.

    PubMed  CAS  Google Scholar 

  8. Aziz MH, Hafeez BB, Sand JM, Pierce DB, Aziz SW, Dreckschmidt NE, Verma AK. Protein kinase C var epsilon mediates Stat3Ser727 phosphorylation, Stat3-regulated gene expression, and cell invasion in various human cancer cell lines through integration with MAPK cascade (RAF-1, MEK1/2, and ERK1/2). Oncogene. 2010;29:3100–9.

    Article  PubMed  CAS  Google Scholar 

  9. Couto JP, Daly L, Almeida A, Knauf JA, Fagin JA, Sobrinho-Simões M, Lima J, Máximo V, Soares P, Lyden D, Bromberg JF. STAT3 negatively regulates thyroid tumorigenesis. Proc Natl Acad Sci USA. 2012;109:E2361–70.

    Article  PubMed  CAS  Google Scholar 

  10. Yan S, Zhou C, Zhang W, Zhang G, Zhao X, Yang S, Wang Y, Lu N, Zhu H, Xu N. Beta-catenin/TCF pathway upregulates STAT3 expression in human esophageal squamous cell carcinoma. Cancer Lett. 2008;271:85–97.

    Article  PubMed  CAS  Google Scholar 

  11. Wang Z, Jin H, Xu R, Mei Q, Fan D. Triptolide downregulates Rac1 and the JAK/STAT3 pathway and inhibits colitis-related colon cancer progression. Exp Mol Med. 2009;41:717–27.

    Article  PubMed  CAS  Google Scholar 

  12. Macha MA, Matta A, Kaur J, Chauhan SS, Thakar A, Shukla NK, Gupta SD, Ralhan R. Prognostic significance of nuclear pSTAT3 in oral cancer. Head Neck. 2011;33:482–9.

    Article  PubMed  Google Scholar 

  13. Wang Z, Zhu S, Shen M, Liu J, Wang M, Li C, Wang Y, Mei Q. STAT3 is involved in esophageal carcinogenesis through regulation of Oct-1. Carcinogenesis. 2013;34:678–88.

    Article  PubMed  CAS  Google Scholar 

  14. Liu J, Shen M, Yue Z, Yang Z, Wang M, Li C, Xin C, Wang Y, Mei Q, Wang Z. Triptolide inhibits colorectal cancer cells proliferation by induction of G1 phase arrest through upregulation of p21. Phytomedicine. 2012;19:756–62.

    Article  PubMed  CAS  Google Scholar 

  15. Wang Z, Liu L, Wang M, Shen M, Li J, Liu J, Li C, Xin C, Zhu S, Mei Q, Wang Y. NOTCH1 regulates migration and invasion of skin cancer cells by E-cadherin repression. Mol Cell Biochem. 2012;32:35–41.

    Article  Google Scholar 

  16. Wang Z, Pedersen E, Basse A, Lefever T, Karine P, Kapoor S, Mei Q, Karlsson R, Brakebusch C. Rac1 is crucial for Ras-dependent skin tumor formation by controlling Pak1-Mek-Erk hyperactivation and hyperproliferation in vivo. Oncogene. 2010;29:3362–73.

    Article  PubMed  CAS  Google Scholar 

  17. Pan YR, Cho KH, Lee HH, Chang ZF, Chen HC. Protein tyrosine phosphatase SHP2 suppresses podosome rosette formation in Src-transformed fibroblasts. J Cell Sci. 2013;126:657–66.

    Article  PubMed  CAS  Google Scholar 

  18. Laczmanska I, Karpinski P, Bebenek M, Sedziak T, Ramsey D, Szmida E, Sasiadek MM. Protein tyrosine phosphatase receptor-like genes are frequently hypermethylated in sporadic colorectal cancer. J Hum Genet. 2013;58:11–5.

    Article  PubMed  CAS  Google Scholar 

  19. Davidson D, Shi X, Zhong MC, Rhee I, Veillette A. The phosphatase PTP-PEST promotes secondary T cell responses by dephosphorylating the protein tyrosine kinase Pyk2. Immunity. 2010;33:167–80.

    Article  PubMed  CAS  Google Scholar 

  20. Sun T, Aceto N, Meerbrey KL, Kessler JD, Zhou C, Migliaccio I, Nguyen DX, Pavlova NN, Botero M, Huang J, Bernardi RJ, Schmitt E, Hu G, Li MZ, Dephoure N, Gygi SP, Rao M, Creighton CJ, Hilsenbeck SG, Shaw CA, Muzny D, Gibbs RA, Wheeler DA, Osborne CK, Schiff R, Bentires-Alj M, Elledge SJ, Westbrook TF. Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell. 2011;144:703–18.

    Article  PubMed  CAS  Google Scholar 

  21. Espejo R, Rengifo-Cam W, Schaller MD, Evers BM, Sastry SK. PTP-PEST controls motility, adherens junction assembly, and Rho GTPase activity in colon cancer cells. Am J Physiol Cell Physiol. 2010;299:C454–63.

    Article  PubMed  CAS  Google Scholar 

  22. Villa-Moruzzi E. Tyrosine phosphatases in the HER2- directed motility of ovarian cancer cells: involvement of PTPN12, ERK5 and FAK. Anal Cell Pathol (Amst). 2011;34:101–12.

    CAS  Google Scholar 

  23. Wu MQ, Hu P, Gao J, Wei WD, Xiao XS, Tang HL, Li X, Ge QD, Jia WH, Liu RB, Xie XM. Low expression of tyrosine-protein phosphatase nonreceptor type 12 is associated with lymph node metastasis and poor prognosis in operable triple-negative breast cancer. Asian Pac J Cancer Prev. 2013;14:287–92.

    Article  PubMed  Google Scholar 

  24. Cao X, Li Y, Luo RZ, He LR, Yang J, Zeng MS, Wen ZS. Tyrosine-protein phosphatase nonreceptor type 12 is a novel prognostic biomarker for esophageal squamous cell carcinoma. Ann Thorac Surg. 2012;93:1674–80.

    Article  PubMed  Google Scholar 

  25. Song JI, Grandis JR. STAT signaling in head and neck cancer. Oncogene. 2000;19:2489–95.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We acknowledge Dr. Zhipeng Wang for preparation of this manuscript.

Conflict of interest

We declare that there is no conflict of interest.

Author information

Authors and Affiliations

  1. DAQIAO Branch, The First Affiliated Hospital of Harbin Medical University, Harbin, China

    Zhe Su & Hong-wen Liu

  2. Department of Stomatology, The Second Hospital of Harbin, Harbin, China

    Hua Tian

  3. Oral Maxillofacial Department, Heilongjiang Province Hospital, Harbin, China

    Hong-quan Song

  4. Department of Stomatology, Nangang Branch of Heilongjiang Province Hospital, Harbin, China

    Rui Zhang

  5. Department of Laboratory Diagnostic, Changhai Hospital, Second Military Medical University, Shanghai, 200433, China

    An-mei Deng

Authors
  1. Zhe Su
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hua Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hong-quan Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rui Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. An-mei Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hong-wen Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to An-mei Deng or Hong-wen Liu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Su, Z., Tian, H., Song, Hq. et al. PTPN12 inhibits oral squamous epithelial carcinoma cell proliferation and invasion and can be used as a prognostic marker. Med Oncol 30, 618 (2013). https://doi.org/10.1007/s12032-013-0618-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-013-0618-4

Keywords

Search

Navigation